166 related articles for article (PubMed ID: 38541221)
41. Obinutuzumab-induced acute thrombocytopenia: Report of two cases and review of literature.
Mechelfekh Y; Pontrucher A; Paillassa J; Temple M; Houot R
Br J Haematol; 2023 Jul; 202(1):168-172. PubMed ID: 37143375
[TBL] [Abstract][Full Text] [Related]
42. Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
Palomba ML; Till BG; Park SI; Morschhauser F; Cartron G; Marks R; Shivhare M; Hong WJ; Raval A; Chang AC; Penuel E; Popplewell LL
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e443-e451. PubMed ID: 35031227
[TBL] [Abstract][Full Text] [Related]
43. Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.
Topp MS; Duell J; Guijarro AMA; Odin M; Nielsen T; Rajeswaran A; Wenger M; Zundel C; Bogucka-Fedorczuk A; Wrobel T
Haematologica; 2020 May; 105(5):e256-e260. PubMed ID: 32029506
[No Abstract] [Full Text] [Related]
44. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Jamois C; Gibiansky E; Gibiansky L; Buchheit V; Sahin D; Cartron G; Marcus R; Hiddemann W; Seymour JF; Strefford JC; Hargreaves CE; Meneses-Lorente G; Frey N; Fingerle-Rowson G
Br J Clin Pharmacol; 2019 Jul; 85(7):1495-1506. PubMed ID: 30866056
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine.
Kuriyama K; Kitamura Y; Tsuji T; Nishikawa R; Nagata H; Ohshiro M; Sugitani M; Hirakawa Y; Matsumoto Y; Iwai T; Uchiyama H
Curr Probl Cancer; 2022 Apr; 46(2):100813. PubMed ID: 34844771
[TBL] [Abstract][Full Text] [Related]
46. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
47. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.
Yamashita-Kashima Y; Yorozu K; Fujimura T; Kawasaki N; Kurasawa M; Yoshiura S; Harada N; Kondoh O; Yoshimura Y
Int J Hematol; 2022 Jun; 115(6):860-872. PubMed ID: 35301681
[TBL] [Abstract][Full Text] [Related]
48. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S; Beldi-Ferchiou A; Alcantara M; Cacheux V; Safar V; Burroni B; Guidez S; Gastinne T; Canioni D; Thieblemont C; Maisonneuve H; Bodet-Milin C; Houot R; Oberic L; Bouabdallah K; Bescond C; Damaj G; Jaccard A; Daguindau N; Moreau A; Tilly H; Ribrag V; Delfau-Larue MH; Hermine O; Macintyre E
Lancet Haematol; 2020 Nov; 7(11):e798-e807. PubMed ID: 32971036
[TBL] [Abstract][Full Text] [Related]
49. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.
Bachy E; Houot R; Feugier P; Bouabdallah K; Bouabdallah R; Virelizier EN; Maerevoet M; Fruchart C; Snauwaert S; Le Gouill S; Marolleau JP; Molina L; Moluçon-Chabrot C; Thieblemont C; Tilly H; Bijou F; Haioun C; Van den Neste E; Fabiani B; Meignan M; Cartron G; Salles G; Casasnovas O; Morschhauser F
Blood; 2022 Apr; 139(15):2338-2346. PubMed ID: 34936697
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.
Zhai J; Qin Y; Zhu J; Song Y; Shen Z; Du X; Jamois C; Brewster M; Shi Y; Shi J
Br J Clin Pharmacol; 2017 Jul; 83(7):1446-1456. PubMed ID: 28072473
[TBL] [Abstract][Full Text] [Related]
51. Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.
Berger T; Shochat T; Aumann S; Nachmias B; Goldschmidt N; Horesh N; Harel R; Aviv A; Shmerts E; Abadi U; Shimony S; Raanani P; Gafter-Gvili A; Gurion R
Ann Hematol; 2023 Aug; 102(8):2127-2136. PubMed ID: 37335322
[TBL] [Abstract][Full Text] [Related]
52. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
[TBL] [Abstract][Full Text] [Related]
53. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
Ohno S; Shoji A; Hatake K; Oya N; Igarashi A
J Med Econ; 2020 Oct; 23(10):1130-1141. PubMed ID: 32620061
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K; Tobinai K; Kinoshita T; Ishikawa T; Hatake K; Ichikawa S; Ohmine K; Kamitsuji Y; Choi I; Chou T; Tsukasaki K; Kumagai K; Taniwaki M; Uchida T; Kikukawa Y; Kubo K; Mihara K; Tsukamoto N; Izutsu K; Yoshida I; Ishida F; Usui N; Iida S; Murayama T; Ueda E; Kuriki H; Ando K
Int J Hematol; 2018 Nov; 108(5):499-509. PubMed ID: 30027429
[TBL] [Abstract][Full Text] [Related]
56. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC; Nowicka M; Hargreaves CE; Burton C; Davies A; Ganderton R; Hiddemann W; Iriyama C; Klapper W; Latham KV; Martelli M; Mir F; Parker H; Potter KN; Rose-Zerilli MJJ; Sehn LH; Trněný M; Vitolo U; Bolen CR; Klein C; Knapp A; Oestergaard MZ; Cragg MS
Blood Adv; 2021 Aug; 5(15):2935-2944. PubMed ID: 34323957
[TBL] [Abstract][Full Text] [Related]
57. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
58. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
[TBL] [Abstract][Full Text] [Related]
59. Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells.
Fujimura T; Yamashita-Kashima Y; Kawasaki N; Yoshiura S; Harada N; Yoshimura Y
Mol Cancer Ther; 2021 Jun; 20(6):1133-1141. PubMed ID: 33850006
[TBL] [Abstract][Full Text] [Related]
60. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
